[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Clinical Hospital Center Rijeka\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":224},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,40,69,89,119,148,174,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100642557","comparison-immune-response-in-paravertebral-and-erector-spinal-plane-block-in-breast-cancer-patients-100642557",false,"NCT07648810","Comparison Immune Response in Paravertebral and Erector Spinal Plane Block in Breast Cancer Patients","Immunologic Response in Breast Cancer Before and After Application of Paravertebral and Erector Spinae Plane Block","IRPVBESP","Inclusion Criteria:\n\n* ASA I and ASA II status, normal BMI\n\nExclusion Criteria:\n\n* ASA III and ASA IV status, coagulopathy, chronic opioid use, diabetes, local infection of the skin","FEMALE","18 Years","70 Years",{"count":21,"type":22},56,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to find the difference in immune response between two types of regional anesthesia in female patients suffering from breast cancer.\n\nThe main question it aims to answer is there a difference in the immune response between paravertebral block and erector spinal plane block.\n\nHypothresis of the study is that paravertebral block with propofol induces less immune response in surgical treatment of breast cancer patients than erector spinal plane block.\n\nParticipants will be asked to sign the informant consent. They will be given either paravertebral block or erector spinae plane block with general anesthesia using propofol. Their venous blood will be taken 1 hour prior surgery and 24 and 48 hours after surgery.",[28],"Breast Cancer - Female","NOT_YET_RECRUITING","2026-06-10",{"date":32,"type":33},"2026-06-15","ACTUAL",{"date":32,"type":22},{"date":36,"type":22},"2027-04-15",{"name":38,"class":39},"Clinical Hospital Center Rijeka","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100627297","ultrasound-scoring-methods-to-monitor-breathing-problems-in-intensive-care-patients-100627297","NCT07446803","Ultrasound Scoring Methods to Monitor Breathing Problems in Intensive Care Patients","Comparison of Lung Ultrasound Protocols for Assessing Pulmonary Function in Intensive Care Patients With Respiratory Failure","UMBPI","Inclusion Criteria:\n\n* Adult patients aged ≥18 years\n* Admitted to the Intensive Care Unit (ICU) Susak\n* Diagnosed with acute respiratory insufficiency\n\nExclusion Criteria:\n\n* Technical inability to perform a lung ultrasound due to patient positioning or other technical reasons\n* Morbid obesity (BMI ≥40 kg\u002Fm²)\n* Serious chest trauma that would compromise assessment\n* Lung pathology that impairs ultrasound visualisation of the desired examination regions","ALL",{"count":50,"type":22},20,"OBSERVATIONAL","The goal of this observational study is to compare two lung ultrasound protocols for assessing lung function in patients with acute respiratory insufficiency treated in intensive care units.\n\nThe main questions it aims to answer are:\n\n1\\. Is there a statistically significant difference between the established Baciarello (name of author) ultrasound protocol (12-point examination) and a new, abbreviated local ultrasound protocol (6-point examination) for assessing lung function? 2. Do the scoring systems of both protocols correlate with each other and with treatment outcomes in critically ill patients? Researchers will compare the Baciarello protocol (assessing 12 fields-6 per side of the body to a new abbreviated local protocol (assessing 6 fields-3 per side of the body) to see if both protocols provide same diagnostic and prognostic information for evaluating lung pathology and patient outcomes.\n\nParticipants will:\n\nUndergo lung ultrasound assessment using both protocols Have their ultrasound findings scored according to each protocol's point system (0-36 for Baciarello; 0-18 for the new abbreviated protocol) Have their arterial blood gas values recorded (pH, PaCO2, PaO2, oxygen saturation) Be monitored for clinical outcomes including mechanical ventilation requirements and hospital mortality",[54],"Acute Respiratory Insufficiency",[56,57,58,59],"Intensive care unit","Acute respiratory failure","Lung ultrasound","Ultrasound protocol","2026-02-27",{"date":62,"type":33},"2026-03-03",{"date":64,"type":22},"2026-03-15",{"date":66,"type":22},"2026-04-15",{"name":38,"class":39},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":88,"locationsCount":4},"100626982","segmental-lung-recruitment-a-randomized-controlled-trial-100626982","NCT07442708","Segmental Lung Recruitment: a Randomized Controlled Trial","Inclusion Criteria:\n\n* treatment in ICU, presence of radiologically or clinically confirmed pulmonary atelectasis during ICU treatment, requirement for mechanical ventilation\n\nExclusion Criteria:\n\n* primary or secondary lung malignancy",{"count":50,"type":22},[25],"This study compares two ways of reopening collapsed parts of the lung in patients on a ventilator.\n\nIn one group, doctors use a small camera (bronchoscope) to guide air pressure directly to the blocked part of the lung. In the other group, increased air pressure is applied to the whole lung using the ventilator.\n\nPatients are carefully monitored to ensure safety.",[79],"Segmental Lung Atelectasis",[81],": Lung atelectasis; Segmental lung recruitment; Mechanical ventilation; Intensive care unit; Recruitment maneuvers","2026-02-24",{"date":84,"type":33},"2026-03-02",{"date":86,"type":22},"2026-02-25",{"date":66,"type":22},{"name":38,"class":39},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":99,"conditions":100,"keywords":105,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":68},"100608423","biomarkers-of-inflammation-and-fibrosis-in-conduction-disorders-after-tavi-100608423","NCT07201363","Biomarkers of Inflammation and Fibrosis in Conduction Disorders After TAVI","The Role of Inflammation and Fibrosis in the Development of Conduction Disorders After Transcatheter Aortic Valve Implantation","Inclusion Criteria:\n\n* Written consent to participate in the trial\n* Diagnosis of severe AS according to current European Society of Cardiology (ESC) guidelines for valvular heart disease\n\nExclusion Criteria:\n\n* Acute infectious disease\n* Chronic inflammatory or autoimmune disease\n* Corticosteroid or other immunosuppressive therapy\n* Active malignant disease\n* Liver disease accompanied by dysfunction\n* Permanent pacemaker implanted previously\n* An acute myocardial infarction within three months before the procedure\n* A surgical procedure within three months before the procedure\n* Previous surgical or transcatheter aortic valve replacement\u002Fimplantation\n* End-stage chronic kidney disease (eGFR \\\u003C15 ml\u002Fmin)",true,{"count":98,"type":22},102,"Prediction of conduction disorders (CDs) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) is an important and complex process with a significant impact on patient outcomes. The goal of this observational prospective trial is to investigate the role of pre-procedural values of systemic biomarkers of inflammation and fibrosis in the prediction of new-onset CDs and permanent pacemaker implantation (PPI) in patients undergoing the TAVI procedure.",[101,102,103,104],"TAVI(Transcatheter Aortic Valve Implantation)","Conduction Disorder","Aortic Stenosis","Permanent Pacemaker Implantation",[103,106,102,107,108,109],"Biomarkers","Fibrosis","Inflammation","Transcatheter Aortic Valve Implantation","RECRUITING","2025-09-30",{"date":113,"type":33},"2025-10-06",{"date":115,"type":33},"2024-12-12",{"date":117,"type":22},"2026-08",{"name":38,"class":39},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":48,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":130,"conditions":131,"keywords":136,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":68},"100602472","the-correlation-between-red-cell-transfusion-and-complications-of-prematurity-100602472","NCT07123948","The Correlation Between Red Cell Transfusion and Complications of Prematurity","The Correlation Between Packed Red Blood Cell Transfusion and Early and Late Complications of Prematurity","Inclusion Criteria:\n\n* all children born as premature infants \\\u003C32. weeks of gestation in Clinical Hospital Centre Rijeka from June 2018. to December 2021. (and who will be on September 2025. six years old)\n* signed informed consent\n\nExclusion Criteria:\n\n* genetic syndromes, severe congenital anomalies","6 Years","7 Years",{"count":129,"type":22},128,"The aim of this clinical trial is to learn if there is a correlation between the erythrocyte transfusion in the early neonatal period in premature infants and early and late complications of prematurity. The main questions it aims to answer are:\n\n* Do premature infants who receive blood transfusions within their first month of life have a higher risk of early prematurity complications, such as retinopathy of prematurity, necrotising enterocolitis, bronchopulmonary dysplasia, and intraventricular haemorrhage?\n* Do premature infants who receive blood transfusions during their first month of life have worse neurological and neurodevelopmental outcomes than those who do not? The first part of the study is retrospective, using data collected from participants' histories. The second part is prospective, evaluating neurological and neurodevelopmental outcomes at the age of six years.",[132,133,134,135],"Retinopathy of Prematurity (ROP)","Bronchopulmonary Dysplasia (BPD)","Enterocolitis, Necrotizing","Intraventricular Hemorrhage Neonatal",[137,138,139],"Infant, Premature;","Erythrocyte Transfusion","Neurodevelopmental Disorder","2025-08-12",{"date":142,"type":33},"2025-08-14",{"date":144,"type":22},"2025-09-01",{"date":146,"type":22},"2029-03-01",{"name":38,"class":39},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":156,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":68},"100600516","de-escalation-in-axillary-surgery-for-early-stage-breast-cancer-100600516","NCT07098507","De-escalation in Axillary Surgery for Early-stage Breast Cancer","Real-world Integration of De-Escalation in Axillary Surgery for Postmenopausal, Early Stage HR+HER2- Breast Cancer Patients","RIDES","Inclusion Criteria:\n\n* newly diagnosed hormone receptor positive, HER2 negative invasive breast cancer or DCIS with microinvasion, histologically confirmed, in postmenopausal patients older than 55 years, with primary tumour up to 3 cm and uninvolved axillary lymph nodes on clinical examination and on axillary ultrasound performed in Clinical Hospital Centre Rijeka. Patients should be eligible for breast conserving surgery and adjuvant whole breast irradiation.\n\nExclusion Criteria:\n\n* Patients younger than 55 years of age and\u002For premenopausal, with cN1-3 status (confirmed cytologically or histologically), or with multiple suspicious lymph nodes on axillary ultrasound, regardless of cytological\u002Fhistological confirmation.\n* Patients diagnosed with pure breast carcinoma in situ (DCIS) without focal invasion\n* Patients with tumour larger than 3 cm or with cT4 status, with de novo metastatic disease\n* Patients with a breast cancer of HER2+ or triple-negative immunophenotype\n* Patients who have received any type of neoadjuvant systemic therapy before surgery and those who have a previous personal history of invasive breast cancer\n* Patients with extensive multifocal or multicentric breast cancer, patients scheduled for mastectomy, partial breast irradiation or who refuse recommended adjuvant systemic oncological treatment\n* Patients who do not wish to participate in a clinical trial","55 Years",{"count":158,"type":22},620,[25],"The goal of this clinical trial is to determine if the omission of sentinel lymph node biopsy is safe for early-stage breast cancer patients in our institution (Clinical Hospital Centre Rijeka).\n\nTargeted group are postmenopausal patients, older than 55 years, diagnosed with hormone-receptor-positive breast cancer, with primary tumour less than 3 cm and unaffected axilla on clinical exam and axillary ultrasound.\n\nThe main questions we aim to answer are:\n\n* if this treatment de-escalation affects patient oncological outcomes (cancer recurrence)?\n* if this treatment de-escalation affects patient clinical outcomes (early and late complications related to axillary surgery)?\n* if this omission of pathological examination of sentinel lymph node affects recommendations on postoperative treatments (irradiation and systemic therapy)? Researchers will compare outcomes between participants submitted to sentinel lymph node biopsy and participants in whom the procedure is omitted to answer those questions.\n\nParticipants will be asked to:\n\n* decide in which group they wish to participate\n* visit the clinic for checkups and tests once every 6 months in first two years and yearly thereafter up to 5 years",[162],"Omitting Sentinel Lymph Node Biopsy in Early-stage Breast Cancer",[164,165],"breast cancer","sentinel lymph node biopsy","2025-07-31",{"date":168,"type":33},"2025-08-01",{"date":170,"type":22},"2025-09-10",{"date":172,"type":22},"2033-09-10",{"name":38,"class":39},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":48,"minAge":4,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100544528","pathophysiological-basis-of-hidradenitis-suppurativa-100544528","NCT06370052","Pathophysiological Basis of Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Hidradenitis Suppurativa\n\nExclusion Criteria:\n\n* patients with no HS\n* patients who do not want to be in the clinical trial",{"count":181,"type":22},50,"HS is a chronic inflammatory disease manifested by recurrent inflammatory nodules, abscesses and tunnels under the skin. This disease is characterized by an inflammatory process that takes place in hair follicles, sebaceous glands and surrounding tissue. Because of its frequent recurrence and chronicity, it represents a major public health problem and there is a need for better diagnosis and new and more effective drugs. This research can be a part of realizing the stated needs.",[184],"Hidradenitis Suppurativa","2025-02-14",{"date":187,"type":33},"2025-02-18",{"date":189,"type":22},"2025-02",{"date":191,"type":22},"2026-12-31",{"name":38,"class":39},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":68},"100532795","the-added-value-of-contrast-enhanced-mammography-to-standard-mammography-in-assessing-the-extent-of-dcis-100532795","NCT06217458","The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS","The Added Value of Contrast Enhanced Mammography (CEM) to Standard Mammography in Assessing the Extent of Ductal Carcinoma in Situ (DCIS)","CEMinDCIS","Inclusion Criteria:\n\n* Patients with pathohistological diagnosis of ductal in situ carcinoma based on samples obtained by vacuum-assisted breast biopsy (VABB) or ultrasound-guided breast biopsy (CNB)\n* Presented at the meeting of the multidisciplinary breast team of the Clinical Hospital Center in Rijeka\n* Patients who underwent surgery at CHC Rijeka and whose pathohistological diagnosis in the final PH report was pure DCIS or microinvasive breast cancer (DCIS with microinvasion)\n* Patients who agree to participate in the study\n\nExclusion Criteria:\n\n* Patients with contraindications for CEM: renal insufficiency (which is ruled out by presenting creatinine and\u002For eGFR results), iodine allergy, pregnancy\u002Flactation, hyperthyroidism\n* Patients who have undergone a preoperative breast MRI\n* Patients who have both DCIS and invasive carcinoma in the preoperative PH report or the final PH report of the surgical material, with the exception of foci with microinvasion (\\\u003C 1 mm).\n* Patients with ipsilateral DCIS recurrence or with previous ipsilateral breast surgery for invasive cancer.\n* Patients\u002Fsubjects whose CEMs do not correspond to the diagnostic interpretation for technical reasons are excluded from the study: insufficient positioning, contrast agent extravasation, failed subtraction\n* Patients under 18 years of age","99 Years",{"count":203,"type":22},100,[25],"The study hypothesis is that the rate of inadequate surgical margins after conservative breast surgery for DICS and the rate of reoperation (re-excision or\u002Fand mastectomy) is lower in the group of patients who underwent standard preoperative mammography and CEM to assess the extent of DICS, compared to the group of patients for whom the preoperative assessment of the extent of in situ breast cancer was not performed using one of the imaging techniques with contrast medium such as contrast mammography or magnetic resonance imaging.",[207,208,209],"DCIS","Breast Carcinoma in Situ","Calcification",[211,212,213,214,215],"Ductal in situ carcinoma","Calcifications","Breast surgery","Screening","Contrast Enhanced Mammography","2025-01-03",{"date":218,"type":33},"2025-01-06",{"date":220,"type":22},"2025-03-01",{"date":222,"type":22},"2027-01-01",{"name":38,"class":39},""]